Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Non-GAAP Adjusted Diluted EPS by Quarter
Non-GAAP Adjusted Diluted EPS ($/share) ($)
Pfizer Non-GAAP Adjusted Diluted EPS: $0.77 in Q2 2026, down 1.3% from a year earlier.
Latest, Q2 2026
0.77
Period ended Jun 28, 2026
Change on a year earlier
-1.3%
0.78 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
“|| Adjusted (3) Diluted EPS | 0.77 | 0.78 | —% | 1.52 | 1.69 | (10%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Non-GAAP Reconciliation Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Non-GAAP Adjusted Diluted EPS ($), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/adj-diluted-eps
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.